Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs) Aurobindo Pharma has received a tentative approval from the US Food and Drug Administration (USFDA) to manufacture and market Losartan Potassium tablets in 25mg, 50mg and 100mg strengths. This is Aurobindo’s 75th abbreviated new drug application (ANDA) approval from the US FDA.
Losartan Potassium tablets are the generic equivalent of US-based Merck Research Laboratories’ Cozaar tablets and falls in the antihypertensive segment. The brand sales of Losartan range of products was $1,235 million for the year ended December 2007 according to Merck's financial disclosures, Aurobindo stated in a press release on Thursday.
